Speed is essential for your in vitro and in vivo screening during drug discovery. Whether you are developing a small or large molecule drug, working with the right bioanalytical team is essential to your success. Look for a partner that provides comprehensive services that include method development, method qualification and sample collection protocol design. Your partner should deliver the right structure, procedures, and data quality that is needed for a successful drug candidate.
Experience a bioanalytical team that offers one of the most extensive technology platforms for small and large molecule bioanalysis. It is comprised of industry-leading instrumentation to support regional and global studies with rapid, precise and reproducible results. Using an existing library of validated methods and state-of-the-art instrumentation, our experienced discovery bioanalytical team has successfully expedited numerous projects to completion.
The bioanalytical team at WuXi AppTec offers optimized project workflows and robust state-of-the-art technology platforms that can rapidly develop and validate methods to support your drug discovery efforts for small and large molecule development. This includes biomarkers, immunogenicity and pharmacokinetic (PK) studies. Learn more about our non-GLP bioanalytical services by watching the video below.
Follow WuXi AppTec Laboratory Testing Division on LinkedIn for industry insights and program support.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
